The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization

banner

POZEN Announces Issuance of VIMOVO® Related Patent

05-Feb-2015 | Source : AG-IP News | Visits : 4601
CHAPEL HILL, N.C - POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, announced in a press release the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer” that relates to VIMOVO®(naproxen/esomeprazole magnesium) delayed release tablets in patients taking low dose aspirin. The patent expires in October 2031.

“This newly issued patent provides additional claims to the VIMOVO patent estate,” stated John R. Plachetka, Chairman, President and Chief Executive Officer. “This patent further demonstrates the continued pattern of innovation by POZEN, which has resulted in 17 issued US Patents and many related foreign patents.”
The USPTO issued US patent number 8,945,621 on February 3, 2015. Horizon Pharma plc (NASDAQ: HZNP), which holds the US NDA for VIMOVO, and POZEN plan to list the US patent in the US Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. This will be the eleventh US patent to be listed in the Orange Book for VIMOVO.

VIMOVO (naproxen/esomeprazole magnesium) is a fixed-dose combination of delayed-release enteric-coated naproxen, a non-steroidal anti-inflammatory drug (NSAID), and immediate-release esomeprazole magnesium, a stomach acid-reducing proton pump inhibitor (PPI), approved for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. VIMOVO is not recommended for use in children younger than 18 years of age. VIMOVO is not recommended for initial treatment of acute pain because the absorption of naproxen is delayed compared to absorption from other naproxen-containing products. Controlled studies do not extend beyond six months. VIMOVO should be used at the lowest dose and for the shortest amount of time as directed by your health care provider.
 
 
 
share



Related Articles